3‐(3,5‐Di‐tert‐butyl‐4‐hydroxyphenyl)‐N′‐[3‐(3,5‐di‐tert‐butyl‐4‐hydroxyphenyl)propanoyl]propanhydrazid
MAK-Begründung
Andrea Hartwig1 (Vorsitz der Ständigen Senatskommission zur Prüfung gesundheitsschädlicher Arbeitsstoffe, Deutsche Forschungsgemeinschaft)MAK Commission2
1 Institut für Angewandte Biowissenschaften, Abteilung Lebensmittelchemie und Toxikologie, Karlsruher Institut für Technologie (KIT), Adenauerring 20a, Geb. 50.41, 76131 Karlsruhe, Deutschland
2 Ständige Senatskommission zur Prüfung gesundheitsschädlicher Arbeitsstoffe, Deutsche Forschungsgemeinschaft, Kennedyallee 40, 53175 Bonn, Deutschland
Abstract
The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has evaluated 3‐(3,5‐di‐tert‐butyl‐4‐hydroxyphenyl)‐N′‐[3‐(3,5‐di‐tert‐butyl‐4‐hydroxyphenyl)propanoyl]‐propanehydrazide [32687‐78‐8] to derive a maximum concentration at the workplace (MAK value), considering all toxicity endpoints. The substance has a low toxicity after repeated oral administration to rats. It is not irritating to skin or eyes. The oral absorption is not known, but is assumed to be significantly less than 100% due to the high molecular mass; however, a MAK value could not be calculated from the oral studies. Therefore, the substance is assigned to Section II b of the List of MAK and BAT Values. No developmental toxicity was observed up to the highest dose of 3000 mg/kg body weight and day in rats. The substance is not genotoxic in vitro or in vivo. Carcinogenicity studies are not available. There are no clinical results on contact sensitization in humans and the substance is not sensitizing in two sensitization test in guinea pigs. Skin absorption was calculated to be so low that it will not contribute significantly to the systemic toxicity.
